Naldemedine: A New Option for OIBD

References

• Leppert W, Zajaczkowska R, Wordliczek J. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation. Expert Opin Pharmacother. 2019;20(5):511–522. doi:10.1080/14656566.2018.1561863
   PubMed Web of Science ®Google Scholar
• Wan Y, Corman S, Gao X, Liu S, Patel H, Mody R. Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain. Am Health Drug Benefits. 2015;8(2):93–102.
   Google Scholar
• Corsetti M, Pannemans J, Whorwell P. Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders? F1000Res. 2019;8:257. doi:10.12688/f1000research.15974.1
   Google Scholar
• Drewes AM, Munkholm P, Simren M, et al. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-recommendations of the nordic working group. Scand J Pain. 2016;11(1):111–122. doi:10.1016/j.sjpain.2015.12.005
   PubMedGoogle Scholar
• Muller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med. 2017;18(10):1837–1863. doi:10.1093/pm/pnw255
   PubMed Web of Science ®Google Scholar
• Mesia R, Virizuela Echaburu JA, Gomez J, Sauri T, Serrano G, Pujol E. Opioid-induced constipation in oncological patients: new strategies of management. Curr Treat Options Oncol. 2019;20(12):91. doi:10.1007/s11864-019-0686-6
   PubMed Web of Science ®Google Scholar
• Haber PS, Elsayed M, Espinoza D, Lintzeris N, Veillard AS, Hallinan R. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. Drug Alcohol Depend. 2017;181:132–139. doi:10.1016/j.drugalcdep.2017.09.024
   PubMed Web of Science ®Google Scholar
• Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150(6):1393–407.
   Web of Science ®Google Scholar
• Simren M, Palsson OS, Whitehead WE. Update on rome IV criteria for colorectal disorders: implications for clinical practice. Curr Gastroenterol Rep. 2017;19(4):15. doi:10.1007/s11894-017-0554-0
   PubMedGoogle Scholar
• Andresen V, Banerji V, Hall G, Lass A, Emmanuel AV. The patient burden of opioid-induced constipation: new insights from a large, multinational survey in five European countries. United Eur Gastroent J. 2018;6(8):1254–1266. doi:10.1177/2050640618786145
   PubMed Web of Science ®Google Scholar
• Imam MZ, Kuo A, Ghassabian S, Smith MT. Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology. 2018;131:238–255. doi:10.1016/j.neuropharm.2017.12.032
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Pergolizzi JV Jr., Giordan E, Locarini P, Boaro A, Billeci D. Tapentadol prolonged release for managing moderate to severe chronic neck pain with or without a neuropathic component. Curr Med Res Opin. 2020:1–9.
   Web of Science ®Google Scholar
• Coluzzi F, Polati E, Freo U, Grilli M. Tapentadol: an effective option for the treatment of back pain. J Pain Res. 2019;12:1521–1528. doi:10.2147/JPR.S190176
   PubMed Web of Science ®Google Scholar
• Kress HG, Coluzzi F. Tapentadol in the management of cancer pain: current evidence and future perspectives. J Pain Res. 2019;12:1553–1560. doi:10.2147/JPR.S191543
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, Coluzzi F, Taylor R Jr. Transdermal buprenorphine for moderate chronic noncancer pain syndromes. Expert Rev Neurother. 2018;23:1–11.
   Google Scholar
• Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: european expert consensus statement. United Eur Gastroent J. 2019;7(1):7–20. doi:10.1177/2050640618818305
   PubMed Web of Science ®Google Scholar
• Galligan JJ, Sternini C. Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance. Handb Exp Pharmacol. 2017;239:363–378.
   PubMedGoogle Scholar
• Hughes PA, Costello SP, Bryant RV, Andrews JM. Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. Am J Physiol Gastrointest Liver Physiol. 2016;311(3):G501–513. doi:10.1152/ajpgi.00442.2015
   Web of Science ®Google Scholar
• Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009;155(1–3):11–17. doi:10.1016/j.regpep.2009.03.012
   PubMed Web of Science ®Google Scholar
• Mark EB, Bødker MB, Grønlund D, Østergaard LR, Frøkjaer JB, Drewes AM. MRI analysis of fecal volume and dryness: validation study using an experimental oxycodone-induced constipation model. J Magn Reson Imaging. 2019;50(3):733–745. doi:10.1002/jmri.26628
   PubMed Web of Science ®Google Scholar
• Mark EB, Klinge MW, Grønlund D, et al. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: effect of opioids. Neurogastroenterol Motil. 2020;32(3):e13753. doi:10.1111/nmo.13753
   Web of Science ®Google Scholar
• Poulsen JL, Brock C, Grønlund D, et al. Prolonged-release oxycodone/naloxone improves anal sphincter relaxation compared to oxycodone plus macrogol 3350. Dig Dis Sci. 2017;62(11):3156–3166. doi:10.1007/s10620-017-4784-7
   Web of Science ®Google Scholar
• Morlion BJ, Mueller-Lissner SA, Vellucci R, et al. Oral prolonged-release oxycodone/naloxone for managing pain and opioid-induced constipation: a review of the evidence. Pain Pract. 2018;18(5):647–665. doi:10.1111/papr.12646
   Web of Science ®Google Scholar
• Mozaffari S, Nikfar S, Abdollahi M. Methylnaltrexone bromide for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2018;19(10):1127–1135. doi:10.1080/14656566.2018.1491549
   PubMed Web of Science ®Google Scholar
• Bui K, Zhou D, Xu H, Floettmann E, Al-Huniti N. Clinical pharmacokinetics and pharmacodynamics of naloxegol, a peripherally acting micro-opioid receptor antagonist. Clin Pharmacokinet. 2017;56(6):573–582. doi:10.1007/s40262-016-0479-z
   Web of Science ®Google Scholar
• Blair HA. Naldemedine: a review in opioid-induced constipation. Drugs. 2019;79(11):1241–1247. doi:10.1007/s40265-019-01160-7
   PubMed Web of Science ®Google Scholar
• Raffa RB, Taylor R Jr, Pergolizzi JV Jr. Treating opioid-induced constipation in patient taking other medications: avoiding CYP450 drug interactions. J Clin Pharm Ther. 2019;44(3):361–371. doi:10.1111/jcpt.12812
   Web of Science ®Google Scholar
• Hu K, Bridgeman MB. Naldemedine (symproic) for the treatment of opioid-induced constipation. P T. 2018;43(10):601–627.
   Google Scholar
• Kubota R, Fukumura K, Wajima T. Population pharmacokinetics and exposure-response relationships of naldemedine. Pharm Res. 2018;35(11):225. doi:10.1007/s11095-018-2501-7
   Web of Science ®Google Scholar
• Kanemasa T, Koike K, Arai T, et al. Pharmacologic effects of naldemedine, a peripherally acting mu-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation. Neurogastroenterol Motil. 2019;31(5):e13563. doi:10.1111/nmo.13563
   Web of Science ®Google Scholar
• Watari R, Matsuda A, Ohnishi S, Hasegawa H. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting mu-opioid receptor antagonist. Drug Metab Pharmacokinet. 2019;34(2):126–133. doi:10.1016/j.dmpk.2018.12.002
   Web of Science ®Google Scholar
• Fukumura K, Yamada T, Yokota T, Kawasaki A. The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of naldemedine. Clin Pharmacol Drug Dev. 2020;9(2):162–174. doi:10.1002/cpdd.690
   Web of Science ®Google Scholar
• Ohnishi S, Fukumura K, Kubota R, Wajima T. Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. Xenobiotica. 2019;49(9):1044–1053. doi:10.1080/00498254.2018.1536815
   PubMed Web of Science ®Google Scholar
• Webster LR, Yamada T, Arjona Ferreira JC. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2017;18(12):2350–2360. doi:10.1093/pm/pnw325
   PubMed Web of Science ®Google Scholar
• Katakami N, Oda K, Tauchi K, et al. Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. J Clin Oncol. 2017;35(17):1921–1928. doi:10.1200/JCO.2016.70.8453
   PubMed Web of Science ®Google Scholar
• Viscusi ER. Clinical overview and considerations for the management of opioid-induced constipation in patients with chronic noncancer pain. Clin J Pain. 2019;35(2):174–188. doi:10.1097/AJP.0000000000000662
   PubMed Web of Science ®Google Scholar
• Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, Phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017;2(8):555–564. doi:10.1016/S2468-1253(17)30105-X
   PubMed Web of Science ®Google Scholar
• Webster LR, Nalamachu S, Morlion B, et al. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain. 2018;159(5):987–994. doi:10.1097/j.pain.0000000000001174
   Web of Science ®Google Scholar
• Saito Y, Yokota T, Arai M, Tada Y, Sumitani M. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies. J Pain Res. 2019;12:127–138. doi:10.2147/JPR.S175900
   Web of Science ®Google Scholar
• Webster LR, Michna E, Khan A, Israel RJ, Harper JR. Long-term safety and efficacy of subcutaneous methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain: a phase 3, open-label trial. Pain Med. 2017;18(8):1496–1504. doi:10.1093/pm/pnx148
   Web of Science ®Google Scholar
• Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771–779. doi:10.1111/apt.12899
   PubMed Web of Science ®Google Scholar
• Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859–3866. doi:10.1200/JCO.2017.73.0853
   PubMed Web of Science ®Google Scholar
• Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol. 2018;29(6):1461–1467. doi:10.1093/annonc/mdy118
   PubMed Web of Science ®Google Scholar
• Wild J, Webster L, Yamada T, Hale M. Safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy: a subgroup analysis of patients ≥ 65 years of age. Drugs Aging. 2020;37(4):271–279. doi:10.1007/s40266-020-00753-2
   Web of Science ®Google Scholar
• Luthra P, Burr NE, Brenner DM, Ford AC. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. Gut. 2018.
   PubMed Web of Science ®Google Scholar
• Sato J, Tanaka R, Ishikawa H, Suzuki T, Shino M. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting. Support Care Cancer. 2020;28(3):1083–1088. doi:10.1007/s00520-019-04884-0
   PubMed Web of Science ®Google Scholar
• NCT03720613 CTg. Risk of major adverse cardiovascular events for naldemedine and other medications for opioid induced constipation in adults with chronic non-cancer pain.
   Google Scholar
• Petrizzi L, Mariscoli M, Valbonetti L, Varasano V, Langhoff JD, Von Rechenberg B. Preliminary study on the effect of parenteral naloxone, alone and in association with calcium gluconate, on bone healing in an ovine “drill hole” model system. BMC Musculoskelet Disord. 2007;8(1):43. doi:10.1186/1471-2474-8-43
   Web of Science ®Google Scholar
• Tanaka K, Kondo H, Hamamura K, Togari A. Systemic administration of low-dose naltrexone increases bone mass due to blockade of opioid growth factor receptor signaling in mice osteoblasts. Life Sci. 2019;224:232–240. doi:10.1016/j.lfs.2019.03.069
   Web of Science ®Google Scholar
• Coluzzi F, Scerpa MS, Centanni M. The effects of opiates on bone formation and bone healing. Curr Osteoporos Rep. 2020. doi:10.1007/s11914-020-00585-4
   Web of Science ®Google Scholar